Intravenous Thrombolysis with Urokinase for Acute Ischemic Stroke.

ABSTRACT:

Background

Intravenous thrombolysis is one of the most effective therapies for the treatment of acute ischemic stroke (AIS), with urokinase offering a cost-effective alternative to newer agents like alteplase and tenecteplase, especially in resource-limited settings.

Methods

This review provides a comprehensive overview of the application of intravenous thrombolysis with urokinase for AIS in the clinical practice of stroke management, including the efficacy, safety, and cost-effectiveness of urokinase compared to other thrombolytic agents.

Results

Urokinase, a first-generation thrombolytic drug, is a non-specific plasminogen activator that offers a cost-effective alternative. It has been used in clinical practice for over two decades to improve neurological outcomes i

SUBMITTER: Qiao Y 

PROVIDER: S-EPMC11505899 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature